Goodpasture's syndrome, known as anti-glomerular basement membrane (anti-GBM) disease, is a rare autoimmune disease that affects both the kidneys and the lungs. As a pioneering force in Goodpasture's syndrome diagnostic innovation, our company provides a variety of diagnostic development services, which include state-of-the-art IVD products, point-of-care testing, and companion diagnostic development services.
Overview of Goodpasture's Syndrome
Goodpasture's syndrome is a rare autoimmune condition marked by the creation of autoantibodies that attack antigens in the basement membranes of the glomeruli and alveoli. This immune response causes inflammation and harm in these organs, leading to kidney failure and lung hemorrhage. In European and Asian populations, the occurrence of anti-GBM disease is approximated to range from 0.5 to 1.8 cases per million individuals annually.
Fig.1 Kidney pathology in anti-GBM disease. (Bharati, J., et al., 2024)
Pathogenesis of Goodpasture's Syndrome
In genetically predisposed individuals, environmental influences like smoking and contact with hydrocarbon solvents can trigger the development of Goodpasture's syndrome. The disease's progression entails the generation of autoantibodies that specifically aim at collagen type IV in the basement membranes of the kidneys and lungs. These antibodies, mainly targeting the non-collagenous segment of the α-3 chain of type IV collagen, prompt inflammatory reactions by activating local complements and enlisting polymorphonuclear leukocytes.
Fig.2 Schematic representation of anti-GBM antibodies development. (Reggiani, F., et al., 2023)
Diagnostics Development for Goodpasture's Syndrome
Accurate differentiation and diagnosis of polymyositis and dermatomyositis rely heavily on identifying specific biomarkers. Cutting-edge research in proteomics and autoantigen profiling is unveiling novel biomarkers, which may lead to more precise diagnostic tools and targeted therapies. Below are vital biomarkers associated with dermatomyositis and polymyositis:
Serological Tests
Serological diagnosis relies on enzyme-linked immunosorbent assay (ELISA) or Luminex-based technologies to detect antibodies. These tests utilize the denatured recombinant NC1 portion ofα3(IV) as the antigenic target.
Genetic Markers
Certain human leukocyte antigen (HLA) types in individuals are associated with increased susceptibility to the disease and a poorer prognosis. Identifying specific genetic factors through genetic testing may aid in early detection.
Immunological Assays
Advancements in immunological assays, including immunofluorescence and immunoblotting techniques, have enhanced the detection of anti-GBM antibodies in individuals with Goodpasture's syndrome.
IVD Kits for Goodpasture's Syndrome
| Kits |
Applications |
Method of detection |
| Human anti-GBM ELISA Kit |
Qualitative detection of anti-GBM antibodies in human serum in vitro |
ELISA |
| Anti-GBM Antibody Detection Kit |
Qualitative detection of anti-GBM antibody |
Indirect immunofluorescence assay (IFA) |
Our Services
Drawing on cutting-edge research and specialized knowledge, we provide diagnostic development solutions that encompass advanced IVD product development services tailored to expedite the creation of effective diagnostic tools for tracking disease progression. Moreover, we offer point-of-care testing and companion diagnostic development services to facilitate the advancement of personalized therapy options.
IVD Product Development Services
By delving into genetic markers associated with Goodpasture's syndrome, we are equipped to devise personalized diagnostic methods and programs, thereby improving early detection of the disease. If you are interested in our services, please don't hesitate to reach out to us for further information and quotations regarding the relevant offerings.
References
- Bharati, Joyita et al. "Anti-Glomerular Basement Membrane Disease: Recent Updates." Advances in kidney disease and health 31.3 (2024): 206-215.
- Reggiani, Francesco et al. "Goodpasture syndrome and anti-glomerular basement membrane disease." Clinical and experimental rheumatology 41.4 (2023): 964-974.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
